Spots Global Cancer Trial Database for EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors
Official Title: An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors
Study ID: NCT01012102
Conditions
Study Description
Brief Summary: To compare 3 doses of EMD 640744 administered by subcutaneous injection in combination with MontanideĀ® ISA 51 VG with regard to immunological efficacy. The primary target variable is the immune response as assessed by ELISPOT before and until week 17 after vaccination with EMD 640744 in MontanideĀ® ISA 51 VG.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Jens-Peter Marschner, MD
Affiliation: Merck KGaA, Darmstadt
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
